Therapeutic properties and safety of recombinant factor VIII and factor IX

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 6, 2009, Pages 403-409

  Zdziarska, Joanna ^a   Chojnowski, Krzysztof ^b   Klukowska, Anna ^c   Łȩtowska, Magdalena ^d   Mital, Andrzej ^e   Podolak Dawidziak, Maria ^f   Windyga, Jerzy ^d   Zawilska, Krystyna ^g,h  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^h J Strus Hospital   (Poland)

Author keywords

Factor IX; Factor VIII; Hemophilia; Plasma derived; Recombinant

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; PATHOGENESIS; REVIEW;

EID: 67650462940     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.721     Document Type: Review

References (49)

1. Lee CA, Berntorp EE, Hoots WK, eds. Textbook of Hemophilia. Oxford. Blackwell Publishing, 2005.
2. [History of hemophilia]. In: Rokicka-Milewska R, ed. [Children with hemophilia]. Warszawa. PZWL, 1992; 14. Polish.
3. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia. 2008; 14 (Suppl 3): 10-18. (Pubitemid 351722377)
4. Ludlam CA, Powderly WG, Bozzette S, et al. Clinical perspectives of emerging pathogens in bleeding disorders. Lancet. 2006; 367: 252-261. (Pubitemid 43107671)
5. Dolan G. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience. Haemophilia. 2006; 12 (Suppl 1): 16-20.
6. Pipe S. Management of hemophilia in the midst of emerging pathogens: a social perspective. Semin Hematol. 2006; 43 (Suppl 3): 1-3.
7. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat hemophilia and other hereditary bleeding disorders. Haemophilia. 2003; 9: 1-23. (Pubitemid 36511629)
8. Kurachi K, Davie EW. Isolation and characterization of a cDNA coding for human factor IX. Proc Natl Acad Sci U S A. 1982; 79: 6461-6464. (Pubitemid 13207514)
9. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984; 312: 326-330. (Pubitemid 15209308)
10. Pipe SW. Recombinant clotting factors. Thromb Haemost. 2008; 99: 840-850.
11. Khrenow AV, Ananyeva NM, Saenko EL. Role of B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X. Blood Coagul Fibrinolysis. 2006; 17: 379-388. (Pubitemid 43941580)
12. White GC, Courter S, Bray GL, et al. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with haemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost. 1997; 77: 660-667.
13. Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004; 10: 428-437. (Pubitemid 39328049)
14. Lusher JM, Lee CA, Kessler CM, et al. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia. 2003; 9: 38-49. (Pubitemid 36511631)
15. Abshire TC, Brackmann HH, Scharrer I, et al. Sucrose formulated recombinant human antihaemophilic factor VIII is safe and efficacious for treatment of haemophilia A in home therapy - International Kogenate-FS Study Group. Thromb Haemost. 2000; 83: 811-816. (Pubitemid 30411675)
16. Bray GL, Gomperts ED, Courier S, et al. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with haemophilia A. The Recombinate Study Group. Blood. 1994; 83: 2428-2435.
17. Lusher JM. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin Thromb Haemost. 2002; 28: 273-276. (Pubitemid 34634341)
18. Négrier C, Shapiro A, Berntorp E, et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost. 2008; 100: 217-223. (Pubitemid 352016311)
19. Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005; 105: 518-525. (Pubitemid 40070730)
20. Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood. 2001; 98: 3600-3606.
21. Ragni MV, Pasi KJ, White GC, et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia. 2002; 8: 91-97. (Pubitemid 35238061)
22. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A - safety, efficacy, and development of Inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med. 1993; 328: 453-459.
23. Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007; 13: 233-243. (Pubitemid 46746045)
24. Schneider B, Fryer JF, Oldenburg J, et al. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia. 2008; 14: 978-986.
25. Brown KE, Simmonds P. Parvoviruses and blood transfusion. Transfusion. 2007; 47: 1745-1750.
26. Soucie JM, Siwak EB, Hooper WC, et al. Universal Data Collection Project Working Group. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion. 2004; 44: 1179-1185.
27. Aledort LM. Issues in making a therapeutic choice: recombinant and/or human-derived products. Haemophilia. 2001; 7 (Suppl 1): 1-3. (Pubitemid 32184433)
28. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion. 1999; 39: 1160-1168.
29. Koplove HM. Cell culture and purification process - purity and safety testing. Ann Hematol. 1994; 68 (Suppl 3): S15-20. (Pubitemid 24126317)
30. Dasgupta S, Repesse Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007; 109: 610-612. (Pubitemid 46105959)
31. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003; 9: 418-435. (Pubitemid 36874391)
32. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006; 107: 46-51. (Pubitemid 43054971)
33. Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia. 2007; 13: 149-155. (Pubitemid 46237946)
34. Gouw SC, van der Bom JG, Auerswald G et al. Recombinant vs. plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007; 109: 4693-4697. (Pubitemid 46827760)
35. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia. 1999; 5: 145-154. (Pubitemid 29326763)
36. Mukovozov I, Sabljic T, Hortelano G, et al. Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. Thromb Haemost. 2008; 99: 874-882. (Pubitemid 351705303)
37. Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol. 2005; 130: 422-427. (Pubitemid 43899592)
38. Morado M, Villar A, Jiménez Yuste V, et al. Prophylactic treatment effects on inhibitor risk: experience in one centre. Hemophilia. 2005; 11: 79-83. (Pubitemid 40468053)
39. Gringeri A, Mannucci PM. Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted. Blood. 2007; 110: 3084. (Pubitemid 350006969)
40. Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost. 2004; 2: 861-862. (Pubitemid 40185728)
41. Lusher JM. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost. 2004; 2: 863-865. (Pubitemid 40192490)
42. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (Survey of Inhibitors in Plasma-product Exposed Toddlers). Haemophilia. 2007; 13 (Suppl 5): 65-68. (Pubitemid 350253407)
43. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997; 78: 261-265.
44. Batile J, Villar A, Liras A, et al. Consensus opinion for the selection and use of therapeutic products for the treatment of hemophilia in Spain. Blood Coagul Fibrinolysis. 2008; 19: 333-340.
45. MASAC recommendations concerning the treatment of hemophilia and other bleeding disorders, revised October 2006 (Document #177), National Hemophilia Foundation.
46. Association of Hemophilia Clinic Directors of Canada. Clinical Practice Guidelines. Hemophilia and von Willebrand disease. CMAJ. 1995; 153: 147-157.
47. Zwart-van Rijkom JE, Plug I, Rosendaal FR, et al. The uptake of recombinant Factor VIII in the Netherlands. Br J Haematol. 2002; 119: 332-341. (Pubitemid 35365478)
48. Santagostino E, Mannucci PM, Bianchi Bonomi A. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia. 2000; 6: 1-10. (Pubitemid 30113894)
49. Windyga J, Chojnowski K, Klukowska A, et al. [Polish management recommendations in hereditary haemorrhagic diatheses against deficits of coagulation factors. Part I: Management rules in haemophilia A and B]. Acta Haematol Pol. 2008; 39: 537-564. Polish.